Revalesio is a clinical-stage pharmaceutical company focused on treating the bioenergetic failure that is the root cause of many conditions that impact human health. Our pioneering research targets the mitochondria ― the cellular engine ― addressing foundational metabolic imbalances. These imbalances drive both the acute damage to the brain and the cerebral vascular system post-stroke, as well as the progressive decline seen in neurodegenerative diseases and aging.

By restoring mitochondrial biogenesis and cellular homeostasis, we aim to transform the quality of life for individuals with neurological conditions without effective therapeutic options. We are not simply treating symptoms; we are re-powering the cell to resist injury and promote recovery.